To evaluate the effects of intravenous ( IV ) golimumab 2 mg/kg + methotrexate ( MTX ) on patient-reported measures of health-related quality of life ( HRQOL ) in patients with active rheumatoid arthritis ( RA ) despite prior MTX therapy .